4uq2 - Revision history

OCA at 09:23, 15 November 2023

2023-11-15T09:23:07Z

←Older revision		Revision as of 09:23, 15 November 2023
Line 4:		Line 4:
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[4uq2]] is a 6 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Synthetic_construct Synthetic construct]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4UQ2 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4UQ2 FirstGlance]. <br>		<table><tr><td colspan='2'>[[4uq2]] is a 6 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Synthetic_construct Synthetic construct]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4UQ2 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4UQ2 FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=XY1:4-[(E)-[5-(2-AZANYLETHYL)-2-OXIDANYL-PHENYL]DIAZENYL]BENZOIC+ACID'>XY1</scene></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.43Å</td></tr>
		+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=XY1:4-[(E)-[5-(2-AZANYLETHYL)-2-OXIDANYL-PHENYL]DIAZENYL]BENZOIC+ACID'>XY1</scene></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4uq2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4uq2 OCA], [https://pdbe.org/4uq2 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4uq2 RCSB], [https://www.ebi.ac.uk/pdbsum/4uq2 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4uq2 ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4uq2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4uq2 OCA], [https://pdbe.org/4uq2 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4uq2 RCSB], [https://www.ebi.ac.uk/pdbsum/4uq2 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4uq2 ProSAT]</span></td></tr>
	</table>		</table>

OCA at 07:31, 29 March 2023

2023-03-29T07:31:54Z

←Older revision		Revision as of 07:31, 29 March 2023
Line 3:		Line 3:
	<StructureSection load='4uq2' size='340' side='right'caption='[[4uq2]], [[Resolution\|resolution]] 2.43Å' scene=''>		<StructureSection load='4uq2' size='340' side='right'caption='[[4uq2]], [[Resolution\|resolution]] 2.43Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[4uq2]] is a 6 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4UQ2 OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4UQ2 FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[4uq2]] is a 6 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Synthetic_construct Synthetic construct]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4UQ2 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4UQ2 FirstGlance]. <br>
-	</td></tr><tr id='~~NonStdRes~~'><td class="sblockLbl"><b>[[~~Non-Standard_Residue~~\|~~NonStd Res~~:]]</b></td><td class="sblockDat"><scene name='pdbligand=XY1:4-[(E)-[5-(2-AZANYLETHYL)-2-OXIDANYL-PHENYL]DIAZENYL]BENZOIC+ACID'>XY1</scene>~~</td></tr>~~	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=XY1:4-[(E)-[5-(2-AZANYLETHYL)-2-OXIDANYL-PHENYL]DIAZENYL]BENZOIC+ACID'>XY1</scene></td></tr>
-	~~<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4uq3\|4uq3]]~~</td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4uq2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4uq2 OCA], [https://pdbe.org/4uq2 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4uq2 RCSB], [https://www.ebi.ac.uk/pdbsum/4uq2 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4uq2 ProSAT]</span></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4uq2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4uq2 OCA], [~~http~~://pdbe.org/4uq2 PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=4uq2 RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/4uq2 PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=4uq2 ProSAT]</span></td></tr>	+
	</table>		</table>
	== Disease ==		== Disease ==
-	[~~[http~~://www.uniprot.org/uniprot/~~B2MG_HUMAN B2MG_HUMAN~~]~~] Defects~~ in ~~B2M~~ are ~~the cause of hypercatabolic hypoproteinemia~~ (~~HYCATHYP~~) ~~[MIM~~:~~[http~~:~~//omim.org/entry/241600 241600]]. Affected individuals show marked reduction in serum concentrations of immunoglobulin and albumin~~, ~~probably due to rapid degradation.<ref>PMID~~:~~16549777</ref> Note=Beta-2~~-~~microglobulin~~ may ~~adopt~~ the ~~fibrillar configuration~~ of ~~amyloid~~ in ~~certain pathologic states~~. ~~The capacity to assemble into amyloid fibrils is concentration dependent. Persistently high beta~~(2)~~-microglobulin serum levels lead~~ to ~~amyloidosis in patients on long~~-~~term hemodialysis~~.<ref>PMID:~~3532124~~</ref> <ref>PMID:~~1336137~~</ref> <ref>PMID:~~7554280~~</ref> <ref>PMID:~~4586824~~</ref> ~~<ref>PMID~~:~~8084451</ref> <ref>PMID~~:~~12119416</ref> <ref>PMID~~:~~12796775</ref>~~ <ref>PMID:~~16901902~~</ref> <ref>PMID:~~16491088~~</ref> ~~<ref>PMID~~:~~17646174</ref>~~ <ref>PMID:~~18835253~~</ref> ~~<ref>PMID~~:~~18395224</ref>~~ <ref>PMID:~~19284997~~</ref>	+	[https://www.uniprot.org/uniprot/HLAA_HUMAN HLAA_HUMAN] Selection of immunotherapy in solid cancer;Birdshot chorioretinopathy;Prediction of phenytoin or carbamazepine toxicity. Alleles A02:01 and A24:02 are associated with increased susceptibility to diabetes mellitus, insulin-dependent (IDDM) (PubMed:22245737, PubMed:18802479, PubMed:16731854, PubMed:22522618). In a glucose-dependent way, allele A02:01 may aberrantly present the signal peptide of preproinsulin (ALWGPDPAAA) on the surface of pancreatic beta cells to autoreactive CD8-positive T cells, potentially driving T-cell mediated cytotoxicity in pancreatic islets (PubMed:22245737, PubMed:18802479). Allele A24:02 may present the signal peptide of preproinsulin (LWMRLLPLL) and contribute to acute pancreatic beta-cell destruction and early onset of IDDM (PubMed:16731854, PubMed:22522618).<ref>PMID:16731854</ref> <ref>PMID:18802479</ref> <ref>PMID:22245737</ref> <ref>PMID:22522618</ref> Allele A03:01 is associated with increased susceptibility to multiple sclerosis (MS), an autoimmune disease of the central nervous system (PubMed:10746785). May contribute to the initiation phase of the disease by presenting myelin PLP1 self-peptide (KLIETYFSK) to autoreactive CD8-positive T cells capable of initiating the first autoimmune attacks (PubMed:18953350).<ref>PMID:10746785</ref> <ref>PMID:18953350</ref> Allele A26:01 is associated with increased susceptibility to Behcet disease (BD) in the Northeast Asian population. Especially in the HLA-B51-negative BD populations, HLA-A26 is significantly associated with the onset of BD.<ref>PMID:30872678</ref> Allele A*29:02 is associated with increased susceptibility to birdshot chorioretinopathy (BSCR). May aberrantly present retinal autoantigens and induce autoimmune uveitis.<ref>PMID:1728143</ref>
	== Function ==		== Function ==
-	[~~[http~~://www.uniprot.org/uniprot/~~1A11_HUMAN 1A11_HUMAN~~]~~] Involved in~~ the ~~presentation~~ of ~~foreign antigens~~ to the ~~immune system~~. ~~[[http~~://~~www~~.~~uniprot~~.~~org~~/~~uniprot~~/~~B2MG_HUMAN B2MG_HUMAN]] Component~~ of the ~~class I major histocompatibility complex~~ (~~MHC~~). ~~Involved~~ in the ~~presentation~~ of peptide antigens to the immune ~~system~~.	+	[https://www.uniprot.org/uniprot/HLAA_HUMAN HLAA_HUMAN] Antigen-presenting major histocompatibility complex class I (MHCI) molecule. In complex with B2M/beta 2 microglobulin displays primarily viral and tumor-derived peptides on antigen-presenting cells for recognition by alpha-beta T cell receptor (TCR) on HLA-A-restricted CD8-positive T cells, guiding antigen-specific T cell immune response to eliminate infected or transformed cells (PubMed:2456340, PubMed:2784196, PubMed:1402688, PubMed:7504010, PubMed:9862734, PubMed:10449296, PubMed:12138174, PubMed:12393434, PubMed:15893615, PubMed:17189421, PubMed:19543285, PubMed:21498667, PubMed:24192765, PubMed:7694806, PubMed:24395804, PubMed:28250417). May also present self-peptides derived from the signal sequence of secreted or membrane proteins, although T cells specific for these peptides are usually inactivated to prevent autoreactivity (PubMed:25880248, PubMed:7506728, PubMed:7679507). Both the peptide and the MHC molecule are recognized by TCR, the peptide is responsible for the fine specificity of antigen recognition and MHC residues account for the MHC restriction of T cells (PubMed:12796775, PubMed:18275829, PubMed:19542454, PubMed:28250417). Typically presents intracellular peptide antigens of 8 to 13 amino acids that arise from cytosolic proteolysis via IFNG-induced immunoproteasome or via endopeptidase IDE/insulin-degrading enzyme (PubMed:17189421, PubMed:20364150, PubMed:17079320, PubMed:26929325, PubMed:27049119). Can bind different peptides containing allele-specific binding motifs, which are mainly defined by anchor residues at position 2 and 9 (PubMed:7504010, PubMed:9862734).<ref>PMID:10449296</ref> <ref>PMID:12138174</ref> <ref>PMID:12393434</ref> <ref>PMID:12796775</ref> <ref>PMID:1402688</ref> <ref>PMID:15893615</ref> <ref>PMID:17079320</ref> <ref>PMID:17189421</ref> <ref>PMID:18275829</ref> <ref>PMID:19542454</ref> <ref>PMID:19543285</ref> <ref>PMID:20364150</ref> <ref>PMID:21498667</ref> <ref>PMID:24192765</ref> <ref>PMID:24395804</ref> <ref>PMID:2456340</ref> <ref>PMID:25880248</ref> <ref>PMID:26929325</ref> <ref>PMID:27049119</ref> <ref>PMID:2784196</ref> <ref>PMID:28250417</ref> <ref>PMID:7504010</ref> <ref>PMID:7506728</ref> <ref>PMID:7679507</ref> <ref>PMID:7694806</ref> <ref>PMID:9862734</ref> Allele A01:01: Presents a restricted peptide repertoire including viral epitopes derived from IAV NP/nucleoprotein (CTELKLSDY), IAV PB1/polymerase basic protein 1 (VSDGGPNLY), HAdV-11 capsid L3/hexon protein (LTDLGQNLLY), SARS-CoV-2 3a/ORF3a (FTSDYYQLY) as well as tumor peptide antigens including MAGE1 (EADPTGHSY), MAGEA3 (EVDPIGHLY) and WT1 (TSEKRPFMCAY), all having in common a canonical motif with a negatively charged Asp or Glu residue at position 3 and a Tyr anchor residue at the C-terminus (PubMed:1402688, PubMed:7504010, PubMed:17189421, PubMed:20364150, PubMed:25880248, PubMed:30530481, PubMed:19177349, PubMed:24395804, PubMed:26758806, PubMed:32887977). A number of HLA-A01:01-restricted peptides carry a post-translational modification with oxidation and N-terminal acetylation being the most frequent (PubMed:25880248). Fails to present highly immunogenic peptides from the EBV latent antigens (PubMed:18779413).<ref>PMID:1402688</ref> <ref>PMID:17189421</ref> <ref>PMID:18779413</ref> <ref>PMID:19177349</ref> <ref>PMID:20364150</ref> <ref>PMID:24395804</ref> <ref>PMID:25880248</ref> <ref>PMID:26758806</ref> <ref>PMID:30530481</ref> <ref>PMID:7504010</ref> Allele A02:01: A major allele in human populations, presents immunodominant viral epitopes derived from IAV M/matrix protein 1 (GILGFVFTL), HIV-1 env (TLTSCNTSV), HIV-1 gag-pol (ILKEPVHGV), HTLV-1 Tax (LLFGYPVYV), HBV C/core antigen (FLPSDFFPS), HCMV UL83/pp65 (NLVPMVATV) as well as tumor peptide antigens including MAGEA4 (GVYDGREHTV), WT1 (RMFPNAPYL) and CTAG1A/NY-ESO-1 (SLLMWITQC), all having in common hydrophobic amino acids at position 2 and at the C-terminal anchors.<ref>PMID:11502003</ref> <ref>PMID:12138174</ref> <ref>PMID:12796775</ref> <ref>PMID:17079320</ref> <ref>PMID:18275829</ref> <ref>PMID:19542454</ref> <ref>PMID:20619457</ref> <ref>PMID:22245737</ref> <ref>PMID:26929325</ref> <ref>PMID:2784196</ref> <ref>PMID:28250417</ref> <ref>PMID:7694806</ref> <ref>PMID:7935798</ref> <ref>PMID:8630735</ref> <ref>PMID:8805302</ref> <ref>PMID:8906788</ref> <ref>PMID:9177355</ref> Allele A03:01: Presents viral epitopes derived from IAV NP (ILRGSVAHK), HIV-1 nef (QVPLRPMTYK), HIV-1 gag-pol (AIFQSSMTK), SARS-CoV-2 N/nucleoprotein (KTFPPTEPK) as well as tumor peptide antigens including PMEL (LIYRRRLMK), NODAL (HAYIQSLLK), TRP-2 (RMYNMVPFF), all having in common hydrophobic amino acids at position 2 and Lys or Arg anchor residues at the C-terminus (PubMed:7504010, PubMed:7679507, PubMed:9862734, PubMed:19543285, PubMed:21943705, PubMed:2456340, PubMed:32887977). May also display spliced peptides resulting from the ligation of two separate proteasomal cleavage products that are not contiguous in the parental protein (PubMed:27049119).<ref>PMID:19543285</ref> <ref>PMID:21943705</ref> <ref>PMID:2456340</ref> <ref>PMID:27049119</ref> <ref>PMID:7504010</ref> <ref>PMID:7679507</ref> <ref>PMID:9862734</ref> Allele A11:01: Presents several immunodominant epitopes derived from HIV-1 gag-pol and HHV-4 EBNA4, containing the peptide motif with Val, Ile, Thr, Leu, Tyr or Phe at position 2 and Lys anchor residue at the C-terminus. Important in the control of HIV-1, EBV and HBV infections (PubMed:10449296). Presents an immunodominant epitope derived from SARS-CoV-2 N/nucleoprotein (KTFPPTEPK) (PubMed:32887977).<ref>PMID:10449296</ref> <ref>PMID:32887977</ref> Allele A23:01: Interacts with natural killer (NK) cell receptor KIR3DL1 and may contribute to functional maturation of NK cells and self-nonself discrimination during innate immune response.<ref>PMID:17182537</ref> Allele A24:02: Presents viral epitopes derived from HIV-1 nef (RYPLTFGWCF), EBV lytic- and latent-cycle antigens BRLF1 (TYPVLEEMF), BMLF1 (DYNFVKQLF) and LMP2 (IYVLVMLVL), SARS-CoV nucleocapsid/N (QFKDNVILL), as well as tumor peptide antigens including PRAME (LYVDSLFFL), all sharing a common signature motif, namely an aromatic residue Tyr or Phe at position 2 and a nonhydrophobic anchor residue Phe, Leu or Iso at the C-terminus (PubMed:9047241, PubMed:12393434, PubMed:24192765, PubMed:20844028). Interacts with natural killer (NK) cell receptor KIR3DL1 and may contribute to functional maturation of NK cells and self-nonself discrimination during innate immune response (PubMed:17182537, PubMed:18502829).<ref>PMID:12393434</ref> <ref>PMID:17182537</ref> <ref>PMID:18502829</ref> <ref>PMID:20844028</ref> <ref>PMID:24192765</ref> <ref>PMID:9047241</ref> Allele A26:01: Presents several epitopes derived from HIV-1 gag-pol (EVIPMFSAL, ETKLGKAGY) and env (LVSDGGPNLY), carrying as anchor residues preferentially Glu at position 1, Val or Thr at position 2 and Tyr at the C-terminus.<ref>PMID:15893615</ref> Allele A29:02: Presents peptides having a common motif, namely a Glu residue at position 2 and Tyr or Leu anchor residues at the C-terminus.<ref>PMID:8622959</ref> Allele A32:01: Interacts with natural killer (NK) cell receptor KIR3DL1 and may contribute to functional maturation of NK cells and self-nonself discrimination during innate immune response.<ref>PMID:17182537</ref> Allele A68:01: Presents viral epitopes derived from IAV NP (KTGGPIYKR) and HIV-1 tat (ITKGLGISYGR), having a common signature motif namely, Val or Thr at position 2 and positively charged residues Arg or Lys at the C-terminal anchor.<ref>PMID:1448153</ref> <ref>PMID:1448154</ref> <ref>PMID:2784196</ref> Allele A74:01: Presents immunodominant HIV-1 epitopes derived from gag-pol (GQMVHQAISPR, QIYPGIKVR) and rev (RQIHSISER), carrying an aliphatic residue at position 2 and Arg anchor residue at the C-terminus. May contribute to viral load control in chronic HIV-1 infection.<ref>PMID:21498667</ref>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 28:		Line 27:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Human~~]]	+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: Grotenbreg~~, G M~~]]	+	[[Category: Synthetic construct]]
-	[[Category: Lescar, J]]	+	[[Category: Grotenbreg GM]]
-	[[Category: Lim~~, P Y~~]]	+	[[Category: Lescar J]]
-	[[Category: Meijers, R]]	+	[[Category: Lim PY]]
-	[[Category: Thong~~, S Y~~]]	+	[[Category: Meijers R]]
-	[[Category: Verhelst~~, S H~~]]	+	[[Category: Thong SY]]
-	[[Category: Yap~~, J W]]~~	+	[[Category: Verhelst SH]]
-	~~[[Category: Azobenzene]]~~	+	[[Category: Yap JW]]
-	~~[[Category: Hla-a]]~~	+
-	~~[[Category: Immune system]]~~	+
-	~~[[Category: Synthetic peptide~~]]	+

OCA at 09:18, 21 May 2019

2019-05-21T09:18:27Z

←Older revision		Revision as of 09:18, 21 May 2019
Line 1:		Line 1:

	==Crystal structure of HLA-A1101 in complex with an azobenzene- containing peptide==		==Crystal structure of HLA-A1101 in complex with an azobenzene- containing peptide==
-	<StructureSection load='4uq2' size='340' side='right' caption='[[4uq2]], [[Resolution\|resolution]] 2.43Å' scene=''>	+	<StructureSection load='4uq2' size='340' side='right'caption='[[4uq2]], [[Resolution\|resolution]] 2.43Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[4uq2]] is a 6 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4UQ2 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4UQ2 FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[4uq2]] is a 6 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4UQ2 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4UQ2 FirstGlance]. <br>
	</td></tr><tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue\|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=XY1:4-[(E)-[5-(2-AZANYLETHYL)-2-OXIDANYL-PHENYL]DIAZENYL]BENZOIC+ACID'>XY1</scene></td></tr>		</td></tr><tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue\|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=XY1:4-[(E)-[5-(2-AZANYLETHYL)-2-OXIDANYL-PHENYL]DIAZENYL]BENZOIC+ACID'>XY1</scene></td></tr>
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4uq3\|4uq3]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4uq3\|4uq3]]</td></tr>
Line 23:		Line 23:

	==See Also==		==See Also==
-	*[[Beta-2 microglobulin\|Beta-2 microglobulin]]	+	*[[Beta-2 microglobulin 3D structures\|Beta-2 microglobulin 3D structures]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Human]]
		+	[[Category: Large Structures]]
	[[Category: Grotenbreg, G M]]		[[Category: Grotenbreg, G M]]
	[[Category: Lescar, J]]		[[Category: Lescar, J]]

OCA at 01:18, 19 January 2017

2017-01-19T01:18:41Z

←Older revision		Revision as of 01:18, 19 January 2017
Line 1:		Line 1:
		+
	==Crystal structure of HLA-A1101 in complex with an azobenzene- containing peptide==		==Crystal structure of HLA-A1101 in complex with an azobenzene- containing peptide==
	<StructureSection load='4uq2' size='340' side='right' caption='[[4uq2]], [[Resolution\|resolution]] 2.43Å' scene=''>		<StructureSection load='4uq2' size='340' side='right' caption='[[4uq2]], [[Resolution\|resolution]] 2.43Å' scene=''>
Line 5:		Line 6:
	</td></tr><tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue\|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=XY1:4-[(E)-[5-(2-AZANYLETHYL)-2-OXIDANYL-PHENYL]DIAZENYL]BENZOIC+ACID'>XY1</scene></td></tr>		</td></tr><tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue\|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=XY1:4-[(E)-[5-(2-AZANYLETHYL)-2-OXIDANYL-PHENYL]DIAZENYL]BENZOIC+ACID'>XY1</scene></td></tr>
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4uq3\|4uq3]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4uq3\|4uq3]]</td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4uq2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4uq2 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4uq2 RCSB], [http://www.ebi.ac.uk/pdbsum/4uq2 PDBsum]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4uq2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4uq2 OCA], [http://pdbe.org/4uq2 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4uq2 RCSB], [http://www.ebi.ac.uk/pdbsum/4uq2 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4uq2 ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
Line 19:		Line 20:
	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>		From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
	</div>		</div>
		+	<div class="pdbe-citations 4uq2" style="background-color:#fffaf0;"></div>

	==See Also==		==See Also==

OCA at 07:58, 26 March 2015

2015-03-26T07:58:33Z

←Older revision		Revision as of 07:58, 26 March 2015
Line 11:		Line 11:
	== Function ==		== Function ==
	[[http://www.uniprot.org/uniprot/1A11_HUMAN 1A11_HUMAN]] Involved in the presentation of foreign antigens to the immune system. [[http://www.uniprot.org/uniprot/B2MG_HUMAN B2MG_HUMAN]] Component of the class I major histocompatibility complex (MHC). Involved in the presentation of peptide antigens to the immune system.		[[http://www.uniprot.org/uniprot/1A11_HUMAN 1A11_HUMAN]] Involved in the presentation of foreign antigens to the immune system. [[http://www.uniprot.org/uniprot/B2MG_HUMAN B2MG_HUMAN]] Component of the class I major histocompatibility complex (MHC). Involved in the presentation of peptide antigens to the immune system.
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Bioorthogonal cleavable linkers are attractive building blocks for compounds that can be manipulated to study biological and cellular processes. Sodium dithionite sensitive azobenzene-containing (Abc) peptides were applied for the temporary stabilization of recombinant MHC complexes, which can then be employed to generate libraries of MHC tetramers after exchange with a novel epitope. This technology represents an important tool for high-throughput studies of disease-specific T cell responses.
		+
		+	Bioorthogonal cleavage and exchange of major histocompatibility complex ligands by employing azobenzene-containing peptides.,Choo JA, Thong SY, Yap J, van Esch WJ, Raida M, Meijers R, Lescar J, Verhelst SH, Grotenbreg GM Angew Chem Int Ed Engl. 2014 Dec 1;53(49):13390-4. doi: 10.1002/anie.201406295., Epub 2014 Oct 27. PMID:25348595<ref>PMID:25348595</ref>
		+
		+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
		+	</div>

	==See Also==		==See Also==

OCA at 11:45, 18 March 2015

2015-03-18T11:45:03Z

←Older revision		Revision as of 11:45, 18 March 2015
Line 11:		Line 11:
	== Function ==		== Function ==
	[[http://www.uniprot.org/uniprot/1A11_HUMAN 1A11_HUMAN]] Involved in the presentation of foreign antigens to the immune system. [[http://www.uniprot.org/uniprot/B2MG_HUMAN B2MG_HUMAN]] Component of the class I major histocompatibility complex (MHC). Involved in the presentation of peptide antigens to the immune system.		[[http://www.uniprot.org/uniprot/1A11_HUMAN 1A11_HUMAN]] Involved in the presentation of foreign antigens to the immune system. [[http://www.uniprot.org/uniprot/B2MG_HUMAN B2MG_HUMAN]] Component of the class I major histocompatibility complex (MHC). Involved in the presentation of peptide antigens to the immune system.
		+
		+	==See Also==
		+	*[[Beta-2 microglobulin\|Beta-2 microglobulin]]
	== References ==		== References ==
	<references/>		<references/>

OCA at 14:55, 5 January 2015

2015-01-05T14:55:46Z

←Older revision		Revision as of 14:55, 5 January 2015
Line 1:		Line 1:
-	'''~~Unreleased structure~~'''	+	==Crystal structure of HLA-A1101 in complex with an azobenzene- containing peptide==
-		+	<StructureSection load='4uq2' size='340' side='right' caption='[[4uq2]], [[Resolution\|resolution]] 2.43Å' scene=''>
-	~~The entry~~ 4uq2 is ~~ON HOLD until Paper Publication~~	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>[[4uq2]] is a 6 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4UQ2 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4UQ2 FirstGlance]. <br>
-	~~Authors~~: ~~Thong~~, S.Y., ~~Yap, J~~.W., ~~Lim, P~~.Y., ~~Verhelst, S~~.H., Lescar, J., Meijers, R., ~~Grotenbreg~~, ~~G.M.~~	+	</td></tr><tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue\|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=XY1:4-[(E)-[5-(2-AZANYLETHYL)-2-OXIDANYL-PHENYL]DIAZENYL]BENZOIC+ACID'>XY1</scene></td></tr>
-		+	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4uq3\|4uq3]]</td></tr>
-	~~Description~~: ~~Crystal structure of HLA~~-~~A1101 in complex with an azobenzene-containing~~ peptide	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4uq2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4uq2 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4uq2 RCSB], [http://www.ebi.ac.uk/pdbsum/4uq2 PDBsum]</span></td></tr>
		+	</table>
		+	== Disease ==
		+	[[http://www.uniprot.org/uniprot/B2MG_HUMAN B2MG_HUMAN]] Defects in B2M are the cause of hypercatabolic hypoproteinemia (HYCATHYP) [MIM:[http://omim.org/entry/241600 241600]]. Affected individuals show marked reduction in serum concentrations of immunoglobulin and albumin, probably due to rapid degradation.<ref>PMID:16549777</ref> Note=Beta-2-microglobulin may adopt the fibrillar configuration of amyloid in certain pathologic states. The capacity to assemble into amyloid fibrils is concentration dependent. Persistently high beta(2)-microglobulin serum levels lead to amyloidosis in patients on long-term hemodialysis.<ref>PMID:3532124</ref> <ref>PMID:1336137</ref> <ref>PMID:7554280</ref> <ref>PMID:4586824</ref> <ref>PMID:8084451</ref> <ref>PMID:12119416</ref> <ref>PMID:12796775</ref> <ref>PMID:16901902</ref> <ref>PMID:16491088</ref> <ref>PMID:17646174</ref> <ref>PMID:18835253</ref> <ref>PMID:18395224</ref> <ref>PMID:19284997</ref>
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/1A11_HUMAN 1A11_HUMAN]] Involved in the presentation of foreign antigens to the immune system. [[http://www.uniprot.org/uniprot/B2MG_HUMAN B2MG_HUMAN]] Component of the class I major histocompatibility complex (MHC). Involved in the presentation of peptide antigens to the immune system.
		+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Grotenbreg, G M]]
		+	[[Category: Lescar, J]]
		+	[[Category: Lim, P Y]]
		+	[[Category: Meijers, R]]
		+	[[Category: Thong, S Y]]
		+	[[Category: Verhelst, S H]]
		+	[[Category: Yap, J W]]
		+	[[Category: Azobenzene]]
		+	[[Category: Hla-a]]
		+	[[Category: Immune system]]
		+	[[Category: Synthetic peptide]]

OCA at 07:22, 27 August 2014

2014-08-27T07:22:51Z

←Older revision		Revision as of 07:22, 27 August 2014
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 4uq2 is ON HOLD until ~~sometime in the future~~	+	The entry 4uq2 is ON HOLD until Paper Publication

	Authors: Thong, S.Y., Yap, J.W., Lim, P.Y., Verhelst, S.H., Lescar, J., Meijers, R., Grotenbreg, G.M.		Authors: Thong, S.Y., Yap, J.W., Lim, P.Y., Verhelst, S.H., Lescar, J., Meijers, R., Grotenbreg, G.M.

	Description: Crystal structure of HLA-A1101 in complex with an azobenzene-containing peptide		Description: Crystal structure of HLA-A1101 in complex with an azobenzene-containing peptide

OCA: Protected "4uq2" [edit=sysop:move=sysop]

2014-06-25T06:08:02Z

Protected "4uq2" [edit=sysop:move=sysop]

←Older revision

Revision as of 06:08, 25 June 2014

OCA: New page: '''Unreleased structure''' The entry 4uq2 is ON HOLD until sometime in the future Authors: Thong, S.Y., Yap, J.W., Lim, P.Y., Verhelst, S.H., Lescar, J., Meijers, R., Grotenbreg, G.M. ...

2014-06-25T06:08:01Z

New page: '''Unreleased structure''' The entry 4uq2 is ON HOLD until sometime in the future Authors: Thong, S.Y., Yap, J.W., Lim, P.Y., Verhelst, S.H., Lescar, J., Meijers, R., Grotenbreg, G.M. ...

New page

'''Unreleased structure'''

The entry 4uq2 is ON HOLD until sometime in the future

Authors: Thong, S.Y., Yap, J.W., Lim, P.Y., Verhelst, S.H., Lescar, J., Meijers, R., Grotenbreg, G.M.

Description: Crystal structure of HLA-A1101 in complex with an azobenzene-containing peptide